Anagenics Ltd has released a press release.
Midkine Antibodies Show Anti-Tumor Activity In Brain Cancer
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Anagenics
- European Midkine Patent For Surgical Adhesion Allowed
- New Publication for Cellmids Midkine Antibody
- Transcript of Cellmid Investor Briefing Call
- CDY: Ikon Legal Action
- USA Distribution Partnership for Cellmids Evolis
Later from Anagenics
- Cellmid records highest ever quarterly sales for evolis
- ASX Market Release - Reinstatement
- Cellmid: Appendix 3Y- Change of Director’s Interest Notice
- USA launch of evolis
- Cellmid receives 831K R&D tax credit
Follow Anagenics into a list and get an email when it puts out news.
Follow Anagenics